Clinical Trial Update: Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ruxolitinib to best available therapy for corticosteroid-refractory acute graft-versus-host disease after allogeneic stem cell transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Corticosteroid Refractory Acute Graft vs Host Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-02-08